Physician profile
Susan Rae
NPI 1437158094
$2,979.96
in general payments reported to CMS, 2019-2025
26 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $275 · 2021: $547 · 2022: $539 · 2023: $559 · 2024: $504 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.52 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $385.63 | 2020-2025 | |
| Lilly USA, LLC | $321.58 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $244.00 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $220.34 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $167.95 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $165.01 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $163.31 | 2020-2023 | Lokelma, Farxiga |
| Amarin Pharma, INC. | $123.54 | 2019-2022 | |
| Amgen INC. | $105.34 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $64.58 | 2019-2025 | Shingrix |
| Abbott Laboratories | $58.92 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $55.82 | 2021-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $54.28 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.43 | 2020-2024 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.12 | 2019-2021 | |
| Axsome Therapeutics, INC. | $32.20 | 2025 | Symbravo |
| Daiichi Sankyo INC. | $29.37 | 2021 | |
| Eisai INC. | $27.20 | 2021 | |
| Shield Therapeutics INC | $19.23 | 2023 | Accrufer |
| Allergan, INC. | $17.05 | 2019 | |
| Ibsa Pharma INC. | $15.45 | 2024 | Tirosint, Licart |
| Gilead Sciences, INC. | $14.55 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.16 | 2019 | |
| Esperion Therapeutics, INC. | $11.74 | 2020 | |
| Althera Pharmaceuticals LLC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Rae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.